EA
ADMS

Emerald Acquisition’s Adamas Pharmaceuticals ADMS Stock Holding History

Emerald Acquisition’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$255K Buy
+15,525
New +$236K ﹤0.01% 2640

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BS
Bow Street New York $52.4M AUM 2.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Emerald Acquisition's ADMS Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Adamas Pharmaceuticals (ADMS) in Q3 2016: 15,525 shares worth $255K. The stake represents ﹤0.01% of the portfolio and ranks #2640 among its holdings.

81 funds tracked by Wall St. Rank hold ADMS as of Q3 2016.

  • Emerald Acquisition held 15,525 shares of Adamas Pharmaceuticals worth $255K as of Q3 2016.
  • Adamas Pharmaceuticals was a new Emerald Acquisition position in Q3 2016.
  • Adamas Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2640 holding.
  • 81 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.